Macrophage folate receptor-β (FR-β) expression in auto-immune inflammatory rheumatic diseases: A forthcoming marker for cardiovascular risk?

Autoimmunity Reviews

Volumn 11, Issue 9, 2012, Pages 621-626

  Jager, Nynke A ^a   Teteloshvili, Nato ^a   Zeebregts, Clark J ^a   Westra, Johanna ^a   Bijl, Marc ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Atherosclerosis; Auto immune inflammatory rheumatic diseases; FR ; Macrophage plasticity; Vulnerable plaques

Indexed keywords

CD14 ANTIGEN; CD163 ANTIGEN; FOLATE RECEPTOR 2;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNE DISEASE; AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASE; CARDIOVASCULAR RISK; EARLY DIAGNOSIS; HUMAN; MACROPHAGE; MACROPHAGE ACTIVATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CELL LINEAGE; CYTOKINES; FOLATE RECEPTOR 2; GENE EXPRESSION; HUMANS; INFLAMMATION; MACROPHAGES;

EID: 84861740754     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.11.002     Document Type: Review

References (60)

1. Anitschkow N. On the morphodynamics of coronary sclerosis of the heart. Acta Pathol Microbiol Scand 1960, 49:426-432.
2. Hansson G.K. Atherosclerosis-an immune disease: The Anitschkov Lecture 2007. Atherosclerosis 2009, 202:2-10.
3. Gremese E., Ferraccioli G. The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 2011, 10:582-589.
4. Mayerl C., Lukasser M., Sedivy R., Niederegger H., Seiler R., Wick G. Atherosclerosis research from past to present-on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. Virchows Arch 2006, 449:96-103.
5. Nussinovitch U., Shoenfeld Y. Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality. Autoimmun Rev 2011, 10:259-266.
6. Cybulsky M.I., Gimbrone M.A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991, 251:788-791.
7. Pasceri V., Yeh E.T. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999, 100:2124-2126.
8. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994, 89:36-44.
9. Clinton S.K., Underwood R., Hayes L., Sherman M.L., Kufe D.W., Libby P. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol 1992, 140:301-316.
10. Pennings M., Meurs I., Ye D., Out R., Hoekstra M., Van Berkel T.J., et al. Regulation of cholesterol homeostasis in macrophages and consequences for atherosclerotic lesion development. FEBS Lett 2006, 580:5588-5596.
11. Smeets T.J., Kraan M.C., Galjaard S., Youssef P.P., Smith M.D., Tak P.P. Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA. Ann Rheum Dis 2001, 60:561-565.
12. Sitia S., Tomasoni L., Atzeni F., Ambrosio G., Cordiano C., Catapano A., et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010, 9:830-834.
13. Zardi E.M., Afeltra A. Endothelial dysfunction and vascular stiffness in systemic lupus erythematosus: Are they early markers of subclinical atherosclerosis?. Autoimmun Rev 2010, 9:684-686.
14. Sattar N., McCarey D.W., Capell H., McInnes I.B. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 108:2957-2963.
15. Svenungsson E., Jensen-Urstad K., Heimburger M., Silveira A., Hamsten A., de Faire U., et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001, 104:1887-1893.
16. Glass C.K., Witztum J.L. Atherosclerosis. the road ahead. Cell 2001, 104:503-516.
17. Moulton K.S., Heller E., Konerding M.A., Flynn E., Palinski W., Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999, 99:1726-1732.
18. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
19. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005, 85:1-31.
20. Boyle J.J., Weissberg P.L., Bennett M.R. Human macrophage-induced vascular smooth muscle cell apoptosis requires NO enhancement of Fas/Fas-L interactions. Arterioscler Thromb Vasc Biol 2002, 22:1624-1630.
21. Virmani R., Burke A.P., Farb A., Kolodgie F.D. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006, 47:C13-C18.
22. Clarke M.C., Figg N., Maguire J.J., Davenport A.P., Goddard M., Littlewood T.D., et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 2006, 12:1075-1080.
23. Husmann M., Barton M. Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease. Expert Opin Investig Drugs 2007, 16:563-567.
24. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5:953-964.
25. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front Biosci 2008, 13:453-461.
26. Stein M., Keshav S., Harris N., Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992, 176:287-292.
27. Stout R.D., Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 2004, 76:509-513.
28. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009, 27:451-483.
29. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
30. Poston R.N., Hussain I.F. The immunohistochemical heterogeneity of atheroma macrophages: comparison with lymphoid tissues suggests that recently blood-derived macrophages can be distinguished from longer-resident cells. J Histochem Cytochem 1993, 41:1503-1512.
31. Waldo S.W., Li Y., Buono C., Zhao B., Billings E.M., Chang J., et al. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol 2008, 172:1112-1126.
32. Boyle J.J., Harrington H.A., Piper E., Elderfield K., Stark J., Landis R.C., et al. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. Am J Pathol 2009, 174:1097-1108.
33. Bouhlel M.A., Derudas B., Rigamonti E., Dievart R., Brozek J., Haulon S., et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007, 6:137-143.
34. Komohara Y., Hirahara J., Horikawa T., Kawamura K., Kiyota E., Sakashita N., et al. AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem 2006, 54:763-771.
35. Khallou-Laschet J., Varthaman A., Fornasa G., Compain C., Gaston A.T., Clement M., et al. Macrophage plasticity in experimental atherosclerosis. PLoS One 2010, 5:e8852.
36. Leidi M., Gotti E., Bologna L., Miranda E., Rimoldi M., Sica A., et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 2009, 182:4415-4422.
37. Mosser D.M. The many faces of macrophage activation. J Leukoc Biol 2003, 73:209-212.
38. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010, 11:889-896.
39. Lennartz M.R., Aggarwal A., Michaud T.M., Feustel P.J., Jones D.M., Brosnan M.J., et al. Ligation of macrophage Fcgamma receptors recapitulates the gene expression pattern of vulnerable human carotid plaques. PLoS One 2011, 6:e21803.
40. Paulos C.M., Varghese B., Widmer W.R., Breur G.J., Vlashi E., Low P.S. Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. Arthritis Res Ther 2006, 8:R77.
41. Matherly L.H., Hou Z., Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007, 26:111-128.
42. Matherly L.H., Goldman D.I. Membrane transport of folates. Vitam Horm 2003, 66:403-456.
43. Elnakat H., Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004, 56:1067-1084.
44. Rothberg K.G., Ying Y.S., Kolhouse J.F., Kamen B.A., Anderson R.G. The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway. J Cell Biol 1990, 110:637-649.
45. Reddy J.A., Haneline L.S., Srour E.F., Antony A.C., Clapp D.W., Low P.S. Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells. Blood 1999, 93:3940-3948.
46. Ross J.F., Wang H., Behm F.G., Mathew P., Wu M., Booth R., et al. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 1999, 85:348-357.
47. Ratnam M., Marquardt H., Duhring J.L., Freisheim J.H. Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA. Biochemistry 1989, 28:8249-8254.
48. Xia W., Hilgenbrink A.R., Matteson E.L., Lockwood M.B., Cheng J.X., Low P.S. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 2009, 113:438-446.
49. van der Heijden J.W., Oerlemans R., Dijkmans B.A., Qi H., van der Laken C.J., Lems W.F., et al. Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum 2009, 60:12-21.
50. Puig-Kroger A., Sierra-Filardi E., Dominguez-Soto A., Samaniego R., Corcuera M.T., Gomez-Aguado F., et al. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res 2009, 69:9395-9403.
51. Matteson E.L., Lowe V.J., Prendergast F.G., Crowson C.S., Moder K.G., Morgenstern D.E., et al. Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan. Clin Exp Rheumatol 2009, 27:253-259.
52. Atzeni F., Turiel M., Hollan I., Meroni P., Sitia S., Tomasoni L., et al. Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. Autoimmun Rev 2010, 9:845-848.
53. Ayala-Lopez W., Xia W., Varghese B., Low P.S. Imaging of atherosclerosis in apolipoprotein e knockout mice: targeting of a folate-conjugated radiopharmaceutical to activated macrophages. J Nucl Med 2010, 51:768-774.
54. Feng Y., Shen J., Streaker E.D., Lockwood M., Zhu Z., Low P.S., et al. A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity. Arthritis Res Ther 2011, 13:R59.
55. Gustafsson C., Mjosberg J., Matussek A., Geffers R., Matthiesen L., Berg G., et al. Gene expression profiling of human decidual macrophages: evidence for immunosuppressive phenotype. PLoS One 2008, 3:e2078.
56. Pollard J.W. Trophic macrophages in development and disease. Nat Rev Immunol 2009, 9:259-270.
57. Bartoloni E., Alunno A., Bistoni O., Gerli R. How early is the atherosclerotic risk in rheumatoid arthritis?. Autoimmun Rev 2010, 9:701-707.
58. Sarzi-Puttini P., Atzeni F., Gerli R., Bartoloni E., Doria A., Barskova T., et al. Cardiac involvement in systemic rheumatic diseases: An update. Autoimmun Rev 2010, 9:849-852.
59. Perrone-Filardi P., Dellegrottaglie S., Rudd J.H., Costanzo P., Marciano C., Vassallo E., et al. Molecular imaging of atherosclerosis in translational medicine. Eur J Nucl Med Mol Imaging 2011, 38:969-975.
60. ten Kate G.L., Sijbrands E.J., Staub D., Coll B., ten Cate F.J., Feinstein S.B., et al. Noninvasive imaging of the vulnerable atherosclerotic plaque. Curr Probl Cardiol 2010, 35:556-591.